3月3日，上海昊海生物科技股份有限公司公布截至2026年2月28日的股份变动月报。公告显示，公司注册股本为人民币230,561,595元，涵盖36,509,740股H股（股票代码：06826）与194,051,855股A股。报告期内，公司无新增发行股份或股本削减，各类股份数量与上月保持一致。
根据公告，公司H股总数与A股总数均未发生变化。截至报告期末，已发行的H股数量为36,509,740股，无库存股；A股则维持在190,203,760股已发行及3,848,095股库存股之合计194,051,855股。公司此前于2025年6月10日回购的580,700股H股仍处于拟注销状态，截至2月底尚未完成注销，整体股本结构因此保持不变。
公告提及，公司本月无其他股份发行、认股权证、可换股票据或股权激励计划的进展事项。公司董事会确认，所有股份变动及相关事宜均遵守香港联合交易所有限公司上市规则及适用法律规定。报告由联席公司秘书田敏签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.